The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine
Open accessAbstract
Gene expression analysis may help the management of cancer patients, allowing the selection of subjects responding to treatment. The aim of this study was the characterization of expression pattern of genes involved in gemcitabine activity in pancreas tumor specimens and its correlation with treatment outcome. The role of drug transport and metabolism on gemcitabine cytotoxicity was examined with specific inhibitors, whereas transcription analysis of human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5′-nucleotidase (5′-NT), cytidine deaminase (CDA), and ribonucleotide reductase subunits M1 and M2 (RRM1 and RRM2) was done by quantitative reverse transcription-PCR in tumor tissue isolated by laser microdissection from surgical or biopsy samples of 102 patients. Association between clinical outcome and gene expression levels was estimated using Kaplan-Meier method and Cox's proportional hazards model. Transport and metabolism had a key role on gemcitabine sensitivity in vitro; moreover, hENT1, dCK, 5′-NT, CDA, RRM1, and RRM2 were detectable in most tumor specimens. hENT1 expression was significantly correlated with clinical outcome. Patients with high levels of hENT1 had a significantly longer overall survival [median, 25.7; 95% confidence interval (95% CI), 17.6-33.7 months in the higher expression tertile versus median, 8.5; 95% CI, 7.0-9.9 months in the lower expression tertile]. Similar results were obtained with disease-free survival and time to disease progression, and the multivariate analysis confirmed the prognostic significance of hENT1. This study suggests that the expression levels of hENT1 may allow the stratification of patients based on their likelihood of survival, thus offering a potential new tool for treatment optimization. (Cancer Res 2006; 66(7): 3928-35)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207272 · Cited by 224
RetractedSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Yeo, C. J., Cameron, J. L., Sohn, T. A., Lillemoe, K. D., Pitt, H. A., Talamini, M. A., Hruban, R. H., Ord, S. E., Sauter, P. K., Coleman, J., et al. (1997) · Annals of Surgery · doi:10.1097/00000658-199709000-00004 · Cited by 1,783
Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,719
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J. D., Dumontet, C., Cass, C., Lai, R., & Mackey, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0224 · Cited by 430
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., & Cass, C. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206952 · Cited by 318
Cited by
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Thomas, D., & Radhakrishnan, P. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0927-5 · Cited by 396
Metadata
- Authors
- Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., Iannopollo, M., Bevilacqua, G., Mosca, F., & Danesi, R.
- Venue
- Cancer Research
- Published
- 2006-04-01
- Volume
- 66
- Issue
- 7
- Pages
- 3928-3935
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2131025996
- Cited by
- 351
- References
- 26
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-4203
- The paper
- Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., Iannopollo, M., Bevilacqua, G., Mosca, F., & Danesi, R. (2006). Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-4203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
